- Independent research carried out by Chinese and Australian scientists shows that the Pressure BioSciences Pressure Cycling Technology (PCT) platform is excellent for the processing of preserved (formalin-fixed paraffin-embedded, or FFPE) and fresh frozen biopsy tissues, which are considered invaluable for discovering cancer biomarkers
- Such tissues play a pivotal role in cancer research and may potentially contribute to the development of therapies and prevention protocols
- Cancer research is one of the more rapidly growing sectors making use of PBIO’s technology; to prepare for further expansion in the future, the company has appointed a new, highly experienced chief financial officer
- The company recently announced that Daniel J. Shea has joined the team as chief financial officer and senior vice president, in anticipation of growth
Pressure BioSciences Inc.’s (OTCQB: PBIO) novel and powerful Pressure Cycling Technology (PCT) platform has performed excellently during the processing of preserved (FFPE) and fresh frozen biopsy tissue samples for the discovery of cancer biomarkers, as indicated by two recently published scientific articles about the technology’s performance.
Independent teams of scientists from China and Australia led the research, and their data suggest that the Pressure BioSciences technology could potentially be used in the clinical diagnostic process based on the cancer biomarkers, as the company noted in a press release (http://ibn.fm/DfmC7). Chinese researchers purchased their first two PCT platforms in 2017 and subsequently purchased four additional systems. In Australia, the PCT platform has been in use since 2016.
Because of the large amount of support data on preserved tissue samples like the ones used in the Chinese and the Australian research studies, such samples are considered invaluable for the retrospective study of disease progression and response to therapy. The use of such samples could speed up the discovery of new therapies and preventative strategies, but, up until now, the successful extraction of high-quality biomolecules from FFPE samples has been difficult to accomplish, at best.
According to Pressure BioSciences president and CEO Richard T. Schumacher, over one billion archival tissue samples exist in pathology and other laboratories across the world. Millions of additional samples are processed and stored every single year. These samples contain an abundance of information that could be key to the discovery of new cancer biomarkers, development of new cancer diagnostics, and release of new treatments and prevention measures, Schumacher concluded.
“We believe that our PCT platform is establishing itself as the method of choice for the superior extraction of potential biomarkers and their presentation for the effective proteomic analyses that will propel the growth of this huge market,” Pressure BioSciences’ director of marketing and sales Roxana McCloskey added.
The global cancer biomarker market is anticipated to reach more than $157 billion by 2022. This is just one of the multiple important applications of Pressure BioSciences’ innovative pressure-based technology platform.
To prepare for the anticipated growth in the years to come, Pressure BioSciences announced a strategic team addition on September 17, 2019. According to an official company announcement, Daniel J. Shea has joined the team as chief financial officer and senior vice president (http://ibn.fm/3rLyE).
Shea has over 30 years of experience in leading and advising financial organizations. Since the beginning of 2017, Shea has operated a CPA advisory firm called Woodcliff Advisors LLC, which provides counsel to boards, CFOs and members of senior management teams.
“PBIO’s unique platform technologies, worldwide customer base, growing revenue stream, and strong management team position the company well to capitalize on substantial growth opportunities across the globe. I stand ready to support the company’s commitment to high-quality financial reporting and internal control as it navigates through these opportunities in the coming years,” Shea said, commenting on the appointment.
For more information, visit the company’s website at www.PressureBioSciences.com
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
